In 2014, ramucirumab, a fully humanized monoclonal antibody that targets angiogenesis by specifically binding to VEGFR-2 with higher affinity than its natural ligand VEGF [35], was approved for the treatment of patients with metastatic NSCLC in second line setting, in combination with docetaxel [36]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.